Literature DB >> 8476032

Postprandial plasma triacylglycerols in rats under alpha 1-adrenergic blockade.

Y Deshaies1, R Belahsen.   

Abstract

The present studies evaluated the effect of prazosin, a selective alpha 1-adrenergic antagonist, on some metabolic determinants of triacylglycerol-rich lipoproteins. Plasma triacylglycerols (TG), TG secretion rate, TG removal rate, plasma insulin, and glucose were evaluated postprandially in animals fed a high-sucrose meal. In the fasted state plasma TG, glucose, and insulin concentrations were minimally affected by prazosin. There was a significant postprandial elevation in plasma TG levels that was larger after ingestion of a meal containing corn oil than after intake of a fat-free meal. Prazosin totally blunted the postprandial elevation in plasma TG independently of the presence (P < 0.004) or absence of dietary fat (P < 0.01). In the postprandial phase after ingestion of a fat-free, high-sucrose meal, prazosin decreased the rate of secretion of TG into the circulation (-54%, P < 0.0003) and accelerated twofold the clearance of an injected fat emulsion (P < 0.02). The postprandial elevations in plasma insulin and glucose were significantly potentiated by administration of prazosin before intake of the fat-free meal. These results indicate that prazosin prevented the postprandial elevation in plasma TG that followed the ingestion of a high-sucrose meal. The results also demonstrate that the alpha 1-blocker exerted its action both by decreasing TG secretion and by increasing the rate of removal of circulating TG.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8476032     DOI: 10.1152/ajpendo.1993.264.4.E541

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  2 in total

Review 1.  Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems.

Authors:  Paul Ernsberger; Richard J Koletsky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-06-17       Impact factor: 3.000

2.  Metabolic benefits of 1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)pyrrolidin-2-one: a non-selective α-adrenoceptor antagonist.

Authors:  Magdalena Kotańska; Katarzyna Kulig; Monika Marcinkowska; Marek Bednarski; Katarzyna Malawska; Paula Zaręba
Journal:  J Endocrinol Invest       Date:  2017-11-07       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.